| 1 |
Lead optimization of Tau-ATTEC as a therapeutic agent for progressive supranuclear palsy |
| TPD |
Taupathy |
Tau |
Lead |
Korea Research Institute of Chemical Technology |
RS-2025-02223246 |
|
| 2 |
Development of Parkinson’s Disease Therapeutics through Degradation of Pathological α-Synuclein Protein Using the SPiDEM Platform |
| TPD |
Parkinson’s disease |
α-synuclein |
Lead |
PRAZER THERAPEUTICS INC. |
RS-2024-00445011 |
|
| 3 |
Preclinical development of an anti-neuroinflammatory drug for the treatment of Parkinson’s disease |
| TPD |
Parkinson's disease |
Neuroinflammation |
Candidate |
Aevisbio, Inc |
RS-2024-00338017 |
|
| 4 |
Development of therapeutic agent for Parkinson's disease targeting alpha synuclein aggregates using autophagy targeting chimera (AUTOTAC) |
| TPD |
Parkinson's disease |
α-Syn |
Hit |
AUTOTAC Bio Inc. |
RS-2022-00166787 |
|